Results 1 to 10 of about 75,185 (305)

L-Dopa-modified microtubules lead to synapse instability in cultured neurons: possible implications in Parkinson’s disease therapy [PDF]

npj Parkinson's Disease
L-Dopa, the main Parkinson’s disease treatment, unexpectedly alters the postsynaptic architecture of cultured mouse neurons through its incorporation into α-tubulin via tubulin tyrosine ligase (TTL).
Agustina Zorgniotti, Aditi Sharma, Sacnicte Ramirez-Rios, Chadni Sanyal, Martina Aleman, Yanina Ditamo, Marie-Jo Moutin, C. Gastón Bisig, Leticia Peris   +8 more
doaj   +2 more sources

Pyrylium based derivatization imaging mass spectrometer revealed the localization of L-DOPA.

PLoS ONE, 2022
Simultaneous imaging of l-dihydroxyphenylalanine (l-DOPA), dopamine (DA) and norepinephrine (NE) in the catecholamine metabolic pathway is particularly useful because l-DOPA is a neurophysiologically important metabolic intermediate.
Shu Taira, Akari Ikeda, Yuki Sugiura, Hitomi Shikano, Shoko Kobayashi, Tsutomu Terauchi, Jun Yokoyama   +6 more
doaj   +1 more source

Effects of L-dopa and p-coumaric acid combination on oxidative stress, DNA damage, and mitochondrial apoptosis in neuroblastoma cells

Bangladesh Journal of Pharmacology, 2023
This study aimed to investigate the effects of levodopa (L-dopa), p-coumaric acid, and combinations in the neuroblastoma (N1E-115) cell. L-dopa and L-dopa plus p-coumaric acid group caused oxidative stress by increasing 12.5 and 3.7-fold in superoxide ...
Nebiye Pelin Turker, Elvan Bakar
doaj   +1 more source

Irreversible incorporation of L-dopa into the C-terminus of α-tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon

Neurobiology of Disease, 2021
L-dopa is the most effective drug used to date for management of Parkinson's disease symptoms. Unfortunately, long-term administration of L-dopa often results in development of motor disorders, including dyskinesias.
Agustina Zorgniotti, Yanina Ditamo, Carlos A. Arce, C. Gaston Bisig   +3 more
doaj   +1 more source

GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming

Neurobiology of Disease, 2020
Levo-dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease; however, most patients develop uncontrollable abnormal involuntary movements known as L-DOPA-induced dyskinesia.
Haruo Nishijima, Fumiaki Mori, Akira Arai, Gang Zhu, Koichi Wakabayashi, Motohiro Okada, Shinya Ueno, Noritaka Ichinohe, Chieko Suzuki, Tomoya Kon, Masahiko Tomiyama   +10 more
doaj   +1 more source

An Overview of Methods for L-Dopa Extraction and Analytical Determination in Plant Matrices

Separations, 2022
L-dopa is a precursor of dopamine used as the most effective symptomatic drug treatment for Parkinson’s disease. Most of the L-dopa isolated is either synthesized chemically or from natural sources, but only some plants belonging to the Fabaceae family ...
Carmen Tesoro, Filomena Lelario, Rosanna Ciriello, Giuliana Bianco, Angela Di Capua, Maria Assunta Acquavia   +5 more
doaj   +1 more source

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease

Frontiers in Neurology, 2020
Levodopa (L-DOPA) is the most effective drug for Parkinson's disease (PD). However, the response to L-DOPA remains individually variable, which hampers the practical value of L-DOPA in the clinic. Genetic factors play a role in L-DOPA efficacy.
Lanting Li, Huixia Lin, Ping Hua, Lei Yan, Hui Dong, Tan Li, Weiguo Liu   +6 more
doaj   +1 more source

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

Journal of Pharmacological Sciences, 2023
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor.
Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, Youji Shoukei, Kazuhiro Soshiroda, Tomoyuki Kanda, Shinichi Uchida   +6 more
doaj   +1 more source

Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39. [PDF]

PLoS ONE, 2014
OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death under oxidative stress. METHODS: PC12 cells were treated with L-DOPA at different concentrations. We detected the L-DOPA induced reactive oxygen
Shi-Ying Zhong, Yong-Xing Chen, Min Fang, Xiao-Long Zhu, Yan-Xin Zhao, Xue-Yuan Liu   +5 more
doaj   +1 more source

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia

Cells, 2023
Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity
Osama F. Elabi, Elena Espa, Katrine Skovgård, Silvia Fanni, Maria Angela Cenci   +4 more
doaj   +1 more source